CD8A and neoplasm: The importance of TYK2 for NK cell- and CD8+ T cell-targeted tumor growth restriction was confirmed by studies with local tumor transplant models, using lymphoma (RMA-S and RMA-Rae1) and adenocarcinoma (MC38) cells [67,76,93].